Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novavax Inc NVAX

Healthcare Biotechnology
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.


NDAQ:NVAX - Post by User

Novavax Inc > far ahead of MRNA on this flu/covid combo shot
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by ProTrader365on Sep 24, 2021 12:43pm
233 Views
Post# 33914398

far ahead of MRNA on this flu/covid combo shot

far ahead of MRNA on this flu/covid combo shotThe same pre market trading pattern was used yesterday, to attempt to set up a tone on the early opening. Low volume, small share blocks...most under 10, being utilized. It came out of the gate strong yesterday, and irrespective of overall futures weakness...I believe it may do the same. The late news last evening about the Ph3 Nano safety and efficacy, is much bigger than anyone may think. They are far, far ahead of MRNA on this flu/covid combo shot...and this news, proves that is indeed the case in a big way! In my humble view. This site > https://bit.ly/3u8gF8h is a must for any trader. I would not want to trade without this amazing tool. Trading without it would be like trading blind.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities